Literature DB >> 21191716

Visual acuity following intravitreal bevacizumab for macular edema associated with retinal vein occlusion.

Masafumi Ota1, Akitaka Tsujikawa, Kazuaki Miyamoto, Atsushi Sakamoto, Tomoaki Murakami, Nagahisa Yoshimura.   

Abstract

PURPOSE: To study prognostic factors for visual acuity (VA) after intravitreal bevacizumab injection (IVB) for macular edema (ME) associated with retinal vein occlusion (RVO), by evaluating the correlation between the final VA and VA at baseline and at 1, 3, and 6 months after the initial IVB.
METHODS: We studied retrospectively 79 eyes of 79 patients with ME secondary to RVO treated with IVB. The correlation between the final VA and VA at each visit was studied by using Pearson's correlation coefficient.
RESULTS: Baseline VA was significantly correlated with the final VA (r = 0.552, P < 0.0001). Postoperative VA at 1, 3, and 6 months after the initial IVB, however, was even more closely correlated with the final VA (r = 0.793, 0.816, 0.893, respectively; P < 0.0001 in each case). Additionally, eyes with a VA of 20/40 or better at 1 month achieved a significantly better final VA than did eyes with a VA worse than 20/40 at 1 month (P < 0.0001). This tendency was seen also in each RVO subgroup.
CONCLUSION: Although the baseline VA was significantly correlated with the final VA, postoperative VA was correlated even more closely with the final VA. VA shortly after the initial IVB seemed to reliably predict final visual outcome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21191716     DOI: 10.1007/s10384-010-0878-x

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  36 in total

1.  Foveal photoreceptor layer in eyes with persistent cystoid macular edema associated with branch retinal vein occlusion.

Authors:  Masafumi Ota; Akitaka Tsujikawa; Tomoaki Murakami; Noritatsu Yamaike; Atsushi Sakamoto; Yuriko Kotera; Kazuaki Miyamoto; Mihori Kita; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2007-11-28       Impact factor: 5.258

2.  Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.

Authors:  Noritatsu Yamaike; Akitaka Tsujikawa; Atsushi Sakamoto; Masafumi Ota; Yuriko Kotera; Kazuaki Miyamoto; Mihori Kita; Nagahisa Yoshimura
Journal:  Retina       Date:  2009-06       Impact factor: 4.256

3.  The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy.

Authors:  Felice Cardillo Piccolino; Roberta Rigault de la Longrais; Giambattista Ravera; Chiara M Eandi; Luca Ventre; Ali' Abdollahi; Marilisa Manea
Journal:  Am J Ophthalmol       Date:  2005-01       Impact factor: 5.258

4.  Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion.

Authors:  H Noma; H Funatsu; M Yamasaki; H Tsukamoto; T Mimura; T Sone; T Hirayama; H Tamura; H Yamashita; A Minamoto; H K Mishima
Journal:  Eye (Lond)       Date:  2006-07-07       Impact factor: 3.775

5.  Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion.

Authors:  Vincenzo Russo; Antonio Barone; Emanuele Conte; Francesco Prascina; Andrea Stella; Nicola Delle Noci
Journal:  Retina       Date:  2009-04       Impact factor: 4.256

6.  Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.

Authors:  Richard F Spaide; Louis K Chang; James M Klancnik; Lawrence A Yannuzzi; John Sorenson; Jason S Slakter; K Bailey Freund; Robert Klein
Journal:  Am J Ophthalmol       Date:  2008-10-17       Impact factor: 5.258

7.  Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion.

Authors:  T C Kreutzer; C S Alge; A H Wolf; D Kook; J Burger; R Strauss; C Kunze; C Haritoglou; A Kampik; S Priglinger
Journal:  Br J Ophthalmol       Date:  2008-01-22       Impact factor: 4.638

8.  Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study.

Authors:  K Kriechbaum; S Michels; F Prager; M Georgopoulos; M Funk; W Geitzenauer; U Schmidt-Erfurth
Journal:  Br J Ophthalmol       Date:  2008-01-22       Impact factor: 4.638

9.  Intravitreal bevacizumab (avastin) in central retinal vein occlusion.

Authors:  Jason Hsu; Richard S Kaiser; Arunan Sivalingam; Prema Abraham; Mitchell S Fineman; Michael A Samuel; James F Vander; Carl D Regillo; Allen C Ho
Journal:  Retina       Date:  2007-10       Impact factor: 4.256

10.  Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.

Authors:  Melvin D Rabena; Dante J Pieramici; Alessandro A Castellarin; Ma'an A Nasir; Robert L Avery
Journal:  Retina       Date:  2007 Apr-May       Impact factor: 4.256

View more
  6 in total

1.  Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab.

Authors:  Narihisa Hanada; Hiroyuki Iijima; Yoichi Sakurada; Mitsuhiro Imasawa
Journal:  Jpn J Ophthalmol       Date:  2011-12-20       Impact factor: 2.447

2.  Foveal sensitivity and visual acuity in macular thickening disorders.

Authors:  Nami Chiba; Mitsuhiro Imasawa; Teruhiko Goto; Masahito Imai; Hiroyuki Iijima
Journal:  Jpn J Ophthalmol       Date:  2012-04-11       Impact factor: 2.447

3.  Predicting visual outcomes for macular disease using optical coherence tomography.

Authors:  Pearse A Keane; Srinivas R Sadda
Journal:  Saudi J Ophthalmol       Date:  2011-01-26

4.  Pars plana vitrectomy combined with internal limiting membrane peeling for recurrent macular edema due to branch retinal vein occlusion after antivascular endothelial growth factor treatments.

Authors:  Yukari Shirakata; Kouki Fukuda; Tomoyoshi Fujita; Yuki Nakano; Hiroyuki Nomoto; Hidetaka Yamaji; Fumio Shiraga; Akitaka Tsujikawa
Journal:  Clin Ophthalmol       Date:  2016-02-05

5.  Metamorphopsia associated with central retinal vein occlusion.

Authors:  Koichiro Manabe; Rie Osaka; Yuki Nakano; Yukari Takasago; Tomoyoshi Fujita; Chieko Shiragami; Kazuyuki Hirooka; Yuki Muraoka; Akitaka Tsujikawa
Journal:  PLoS One       Date:  2017-10-19       Impact factor: 3.240

6.  Metamorphopsia Associated with Branch Retinal Vein Occlusion.

Authors:  Koichiro Manabe; Akitaka Tsujikawa; Rie Osaka; Yuki Nakano; Tomoyoshi Fujita; Chieko Shiragami; Kazuyuki Hirooka; Akihito Uji; Yuki Muraoka
Journal:  PLoS One       Date:  2016-04-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.